Protein Sciences received FDA approval for its new flu vaccine, Flublok, for patients aged 18 to 49. The vaccine "offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus," an agency official said. The production method uses recombinant DNA and insect virus expression technology, which have been used in other vaccines.
FDA approves Protein Sciences' flu vaccine Flublok
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||